Researchers combined a vaccine using the same mRNA technology as many COVID-19 jabs with an established immunotherapy called pembrolizumab. It was given to patients after they had surgery to remove stage 3 or stage 4 melanoma.

Credits: Unsplash; Author: @nci;

After three years, 75 percent of those who had the vaccine were still cancer-free, compared to 56 percent of people who only received pembrolizumab.